Each dot is one of the 60 Biotechnology stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 21.7% and the median P/E 18.16. Pinned to the edge: 5 outliers on X and 2 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | LLYEli Lilly | 49.6% | 42.85 | $1.14T | Pharmaceuticals |
| 2 | JNJJohnson & Johnson | 7.8% | 39.80 | $640.64B | Pharmaceuticals |
| 3 | ABBVAbbVie | 10.4% | 80.31 | $506.78B | Pharmaceuticals |
| 4 | MRKMerck | 4.6% | 109.72 | $348.15B | Pharmaceuticals |
| 5 | AZNAstrazeneca | 9.4% | 25.41 | $265.47B | Pharmaceuticals |
| 6 | AMGNAmgen | 9.1% | 27.31 | $238.78B | Biotechnology |
| 7 | VRTXVertex Pharmaceuticals | 10.2% | 29.64 | $130.55B | Biotechnology |
| 8 | BMYBristol Myers Squibb | 3.1% | 13.51 | $125.38B | Pharmaceuticals |
| 9 | GSKGsk | 87.0% | 7.83 | $103.67B | Pharmaceuticals |
| 10 | REGNRegeneron Pharmaceuticals | 9.3% | 19.07 | $82.57B | Biotechnology |
| 11 | TAKTakeda Pharmaceutical | 0.7% | 112.03 | $64.34B | Pharmaceuticals |
| 12 | ARGXArgenx Se | 61.5% | 28.54 | $53.57B | Biotechnology |
| 13 | SNYSanofi | 27.7% | 10.92 | $50.89B | Pharmaceuticals |
| 14 | TEVATeva Pharmaceutical Industries | 4.1% | 65.85 | $46.49B | Generic Drugs |
| 15 | ONCBeOne Medicines | 34.3% | 63.19 | $41.44B | Pharmaceuticals |
| 16 | BIIBBiogen | 0.3% | 44.41 | $37.06B | Biotechnology |
| 17 | ALNYAlnylam Pharmaceuticals | 90.1% | 41.30 | $30.28B | Biotechnology |
| 18 | INCYIncyte | 26.9% | 14.07 | $22.69B | Pharmaceuticals |
| 19 | ZBHZimmer Biomet Holdings | 8.6% | 23.03 | $18.58B | Medical Devices |
| 20 | EXELExelixis | 9.2% | 18.96 | $16.32B | Pharmaceuticals |
| 21 | HALOHalozyme Therapeutics | 41.2% | 36.06 | $14.92B | Biotechnology |
| 22 | ASNDAscendis Pharma A | 128.4% | 17.16 | $14.88B | Biotechnology |
| 23 | NBIXNeurocrine Biosciences | 34.4% | 20.66 | $14.58B | Pharmaceuticals |
| 24 | JAZZJazz Pharmaceuticals | 12.6% | 13.95 | $13.13B | Pharmaceuticals |
| 25 | RDYDr Reddys Laboratories | -10.5% | 31.49 | $11.45B | Generic Drugs |
| 26 | GMEDGlobus Medical | 19.7% | 20.51 | $10.98B | Medical Devices |
| 27 | BMRNBiomarin Pharmaceutical | 11.2% | 148.48OUT | $10.83B | Biotechnology |
| 28 | PTGXProtagonist Therapeutics | 34.8% | 111.77 | $9.27B | Biotechnology |
| 29 | TGTXTg Therapeutics | 76.1% | 17.36 | $7.66B | Biotechnology |
| 30 | LGNDLigand Pharmaceuticals | 54.9% | 31.00 | $6.11B | Biotechnology |
| 31 | KNSAKiniksa Pharmaceuticals International | 58.9% | 69.10 | $5.57B | Biotechnology |
| 32 | ARQTArcutis Biotherapeutics | 76.1% | 144.90OUT | $4.13B | Biotechnology |
| 33 | GMABGenmab A | 23.6% | 3.26 | $2.89B | Biotechnology |
| 34 | NRIXNurix Therapeutics | 738.8%OUT | 9.66 | $2.85B | Biotechnology |
| 35 | ADMAAdma Biologics | 8.0% | 14.85 | $2.51B | Biotechnology |
| 36 | AUPHAurinia Pharmaceuticals | 19.8% | 7.03 | $2.21B | Pharmaceuticals |
| 37 | HRMYHarmony Biosciences Holdings | 24.3% | 11.71 | $2.12B | Pharmaceuticals |
| 38 | LKFTLakefront Biotherapeutics | 179.7% | 3.02 | $2.09B | Biotechnology |
| 39 | OMEROmeros | 1,532%OUT | 9.53 | $1.19B | Biotechnology |
| 40 | RIGLRigel Pharmaceuticals | 3.3% | 2.86 | $919.63M | Biotechnology |
| 41 | TBPHTheravance Biopharma | 35.1% | 16.35 | $883.70M | Biotechnology |
| 42 | ABUSArbutus Biopharma | 1,079%OUT | 5.44 | $832.34M | Biotechnology |
| 43 | PHARPharming | 1.9% | 43.32 | $816.89M | Biotechnology |
| 44 | CRMDCorMedix | 208.3% | 3.76 | $627.55M | Pharmaceuticals |
| 45 | IRWDIronwood Pharmaceuticals | 26.2% | 4.40 | $571.31M | Biotechnology |
| 46 | ZVRAZevra Therapeutics | 119.6% | 9.72 | $566.12M | Pharmaceuticals |
| 47 | PBYIPuma Biotechnology | -2.9% | 20.86 | $555.75M | Biotechnology |
| 48 | ARVNArvinas | -15.0% | 50.90 | $473.36M | Biotechnology |
| 49 | KMDAKamada | 13.2% | 20.61 | $455.41M | Biotechnology |
| 50 | AGENAgenus | 30.5% | 2.83 | $259.60M | Biotechnology |
| 51 | PLXProtalix BioTherapeutics | 30.1% | 10.53 | $199.57M | Biotechnology |
| 52 | CGENCompugen | 234.2%OUT | 5.06 | $177.98M | Biotechnology |
| 53 | QTTBQ32 Bio | 294.2%OUT | 43.03 | $171.89M | Biotechnology |
| 54 | VXRTVaxart | 201.1% | 2.57 | $99.29M | Biotechnology |
| 55 | RLYBRallybio | -15.1% | 2.07 | $94.18M | Biotechnology |
| 56 | SPROSpero Therapeutics | -3.3% | 8.39 | $62.03M | Biotechnology |
| 57 | FBIOFortress Biotech | 16.1% | 7.08 | $59.13M | Biotechnology |
| 58 | ELUTElutia | -0.3% | 0.79 | $35.99M | Medical Devices |
| 59 | KYNBKyntra Bio | 3.0% | 0.10 | $18.22M | Biotechnology |
| 60 | PTIXProtagenic Therapeutics, Inc.\new | -34.5% | 0.25 | $1.34M | Biotechnology |
Among Biotechnology stocks, the largest companies growing revenue faster than the median (21.7%) while trading below the median P/E (18.16) are Gsk (GSK), Sanofi (SNY), Incyte (INCY), Ascendis Pharma A (ASND) and Tg Therapeutics (TGTX). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Astrazeneca (AZN) and Amgen (AMGN).
The median P/E across the 60 Biotechnology stocks plotted is 18.16, with the middle half between 7.64 and 40.18.
The median is 21.7%, with the middle half between 7.0% and 59.5%.
The rank correlation (Spearman) is -0.10, a no meaningful negative relationship: knowing one tells you little about the other.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 5 companies are outliers on Revenue Growth (1y) (TTM) and 2 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry is included unless you choose primary industry only. Nothing on this page is investment advice.